BLATOPICALGEL
Approved
Dec 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
NEXOBRID (anacaulase-bcdb) by MediWound is eschar. First approved in 2022.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEXOBRID (anacaulase-bcdb) is a topical gel biologic approved in December 2022 for enzymatic debridement of burn wounds. It works by dissolving necrotic tissue (eschar), though the specific active components have not been fully characterized. The product represents a novel approach to burn wound management in acute care settings.
Peak
Early-stage peak phase product with moderate competitive pressure (30%) suggests ongoing market penetration and potential for commercial team expansion.
Mechanism of Action
eschar. The specific components responsible for this effect have not been identified.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns
Started May 2015
175 enrolled
Thermal Burns
A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care
Started May 2015
145 enrolled
Thermal Burns
Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries
Thermal Burn
Career Relevance
NEXOBRID is a niche, specialized acute care product requiring field expertise in burn centers and trauma networks. Career opportunities are concentrated in specialty sales and medical affairs roles targeting a limited but high-value customer base.
Worked on NEXOBRID at MediWound? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.